PEPMA's goal is to target ultra-rare genetic disorders in a 12 month time-frame and quickly match patients to extremely specific treatments as efficiently as possible.
Recursion's cutting-edge approach, paired with the experience of its partners in PEPMA, has the transformational potential to drive this research.